PL377731A1 - Sposoby hodowli komórek ssaczych do wytwarzania białka - Google Patents
Sposoby hodowli komórek ssaczych do wytwarzania białkaInfo
- Publication number
- PL377731A1 PL377731A1 PL377731A PL37773103A PL377731A1 PL 377731 A1 PL377731 A1 PL 377731A1 PL 377731 A PL377731 A PL 377731A PL 37773103 A PL37773103 A PL 37773103A PL 377731 A1 PL377731 A1 PL 377731A1
- Authority
- PL
- Poland
- Prior art keywords
- cell culture
- mammalian cell
- protein production
- culture processes
- processes
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title 1
- 210000004962 mammalian cell Anatomy 0.000 title 1
- 230000014616 translation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/74—Undefined extracts from fungi, e.g. yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/905—Hyaluronic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43610102P | 2002-12-23 | 2002-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL377731A1 true PL377731A1 (pl) | 2006-02-06 |
Family
ID=32682337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL377731A PL377731A1 (pl) | 2002-12-23 | 2003-12-18 | Sposoby hodowli komórek ssaczych do wytwarzania białka |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7541164B2 (pl) |
| EP (1) | EP1575998A4 (pl) |
| JP (1) | JP4541157B2 (pl) |
| KR (1) | KR20050088136A (pl) |
| CN (2) | CN101044239B (pl) |
| AU (1) | AU2003300276B2 (pl) |
| BR (1) | BR0317723A (pl) |
| CA (1) | CA2511520A1 (pl) |
| MX (1) | MXPA05006523A (pl) |
| PL (1) | PL377731A1 (pl) |
| TW (1) | TWI312368B (pl) |
| WO (1) | WO2004058800A2 (pl) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| MXPA03010568A (es) | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
| DE60335024D1 (de) | 2002-12-23 | 2010-12-30 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
| AU2004264901B2 (en) | 2003-08-04 | 2009-12-10 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| JP2008504009A (ja) * | 2003-12-23 | 2008-02-14 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 腫瘍壊死因子結合蛋白質を生産する方法 |
| US7815765B2 (en) * | 2004-04-01 | 2010-10-19 | Swei Mu Wang | Method for forming laminated synthetic leather |
| CN101198347A (zh) | 2005-04-06 | 2008-06-11 | 布里斯托尔-迈尔斯斯奎布公司 | 使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法 |
| EP2267024B1 (en) * | 2005-06-03 | 2012-05-09 | Ares Trading S.A. | Production of recombinant Il-18 binding protein |
| AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| AU2006330922B2 (en) * | 2005-12-20 | 2012-07-26 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
| AR058568A1 (es) * | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| BRPI0716762A2 (pt) | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
| JP5586235B2 (ja) * | 2007-03-02 | 2014-09-10 | ワイス・エルエルシー | ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用 |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| WO2010016943A2 (en) | 2008-08-08 | 2010-02-11 | Biogen Idec Ma Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
| TWI610936B (zh) | 2008-10-20 | 2018-01-11 | 艾伯維有限公司 | 使用蛋白質ａ親和性層析進行抗體之分離及純化 |
| TW201028433A (en) | 2008-10-20 | 2010-08-01 | Abbott Lab | Viral inactivation during purification of antibodies |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| US8642557B2 (en) | 2010-03-12 | 2014-02-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
| ES2533074T3 (es) | 2010-04-26 | 2015-04-07 | Novartis Ag | Medio de cultivo celular mejorado |
| RU2577972C2 (ru) * | 2010-04-26 | 2016-03-20 | Новартис Аг | Способ получения рекомбинантного полипептида |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| EP2729561A4 (en) | 2011-07-08 | 2015-06-24 | Momenta Pharmaceuticals Inc | CELL CULTURE METHOD |
| CN102634476A (zh) * | 2012-03-01 | 2012-08-15 | 江苏太平洋美诺克生物药业有限公司 | 高耐受细胞株的筛选方法 |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| CN104364369B (zh) | 2012-05-02 | 2018-09-07 | 生命技术公司 | 哺乳动物细胞中使用独特的高密度生长和转染培养基与表达增强剂对的高产量瞬时表达 |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| KR101380740B1 (ko) * | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| EP2867251B1 (en) | 2012-06-29 | 2019-08-21 | Bristol-Myers Squibb Company | Methods for reducing glycoprotein aggregation |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| HK1211981A1 (en) | 2012-09-02 | 2016-06-03 | Abbvie Inc. | Methods to control protein heterogeneity |
| CN104822826B (zh) | 2012-10-15 | 2019-04-30 | 百时美施贵宝公司 | 用于蛋白产生的哺乳动物细胞培养过程 |
| US20140106405A1 (en) * | 2012-10-15 | 2014-04-17 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151230A2 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Method of treating granulomatosis with polyangiitis |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US20170042972A1 (en) | 2014-04-25 | 2017-02-16 | Chetan KARYEKAR | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| JP6652334B2 (ja) | 2014-05-31 | 2020-02-19 | Ｊｃｒファーマ株式会社 | ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地 |
| CN106687575B (zh) | 2014-06-04 | 2021-04-30 | 美国安进公司 | 用于收获哺乳动物细胞培养物的方法 |
| JP6471855B2 (ja) * | 2015-02-18 | 2019-02-20 | 澁谷工業株式会社 | スケジュール管理システム |
| EP3072957B1 (en) | 2015-03-23 | 2019-07-10 | Lonza Ltd | Methods for controlling protein glycosylation |
| EP4089109A3 (en) * | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| KR102669726B1 (ko) * | 2015-07-13 | 2024-05-29 | 라이프 테크놀로지스 코포레이션 | Cho 세포에서의 개선된 일시적 단백질 발현을 위한 시스템 및 방법 |
| WO2017065559A1 (ko) | 2015-10-15 | 2017-04-20 | (주)알테오젠 | Igg fc 도메인을 가지는 융합 단백질의 생산방법 |
| KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| KR101789509B1 (ko) * | 2015-11-05 | 2017-10-26 | 주식회사 프로젠 | 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 생산 방법 |
| RU2018128582A (ru) * | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
| JP7213180B2 (ja) * | 2016-10-19 | 2023-01-26 | エフ．ホフマン－ラ ロシュ アーゲー | 免疫コンジュゲートを製造するための方法 |
| AU2018256256B2 (en) * | 2017-04-21 | 2023-02-23 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| CN110628700B (zh) * | 2019-10-14 | 2023-10-17 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 一种用于筛选细胞培养条件的标准方法 |
| CN113215078A (zh) * | 2020-01-21 | 2021-08-06 | 上海药明生物技术有限公司 | 利用麦芽糖进行cho细胞培养的方法 |
| KR20230045615A (ko) * | 2020-08-14 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질을 제조하는 방법 |
| WO2022172959A1 (ja) * | 2021-02-09 | 2022-08-18 | 株式会社彩 | 細胞処理剤 |
| CN112608906B (zh) * | 2021-03-08 | 2021-05-18 | 上海奥浦迈生物科技股份有限公司 | 一种cho细胞组合糖类补料培养基 |
| WO2022208550A1 (en) * | 2021-03-31 | 2022-10-06 | Dr. Reddy's Laboratories Limited | Cell culture process for fusion protein composition |
| JP2022184798A (ja) * | 2021-06-01 | 2022-12-13 | ファイザー・インク | ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法 |
| CN116121170B (zh) * | 2023-02-09 | 2025-11-25 | 上海药明生物技术有限公司 | 一种降低哺乳动物细胞表达系统所产高甘露糖型糖蛋白水平的方法及其应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4357422A (en) | 1980-08-14 | 1982-11-02 | Massachusetts Institute Of Technology | Method of enhancing interferon production |
| US4994387A (en) | 1983-11-10 | 1991-02-19 | The Wistar Institute | Process and medium for cloning and long-term serial cultivation of human endothelial cells |
| US5132223A (en) | 1983-11-10 | 1992-07-21 | Thomas Jefferson University | Process and medium for cloning and long-term serial cultivation of adult human endothelial cells |
| CA2003455C (en) | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US7070776B1 (en) | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
| US5318898A (en) | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| TW318142B (pl) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| KR100238712B1 (ko) | 1991-06-27 | 2000-01-15 | 스티븐 비. 데이비스 | 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도 |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| EP0637963B1 (en) | 1992-04-07 | 2004-08-04 | The Regents of the University of Michigan | Cd28 pathway immunoregulation |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US5348877A (en) | 1993-03-12 | 1994-09-20 | Boyce Thompson Institute For Plant Research, Inc. | Method of adapting anchorage-dependent cell lines to suspension conditions |
| WO1994028912A1 (en) | 1993-06-10 | 1994-12-22 | The Regents Of The University Of Michigan | Cd28 pathway immunosuppression |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| CN1143116A (zh) * | 1995-04-14 | 1997-02-19 | 沈阳三生药业有限公司 | 一种新的人红细胞生成素 |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5728580A (en) * | 1996-02-20 | 1998-03-17 | Cornell Research Foundation, Inc. | Methods and culture media for inducing single cell suspension in insect cell lines |
| PT892643E (pt) | 1996-03-20 | 2002-09-30 | Univ Emory | Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito |
| US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| WO1998008934A1 (en) * | 1996-08-30 | 1998-03-05 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
| ZA98533B (en) | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US20030219863A1 (en) | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| AU4314299A (en) * | 1998-05-29 | 1999-12-13 | Genentech Inc. | Cell culture process for producing glycoproteins |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| DE60032349T2 (de) * | 1999-04-26 | 2007-07-12 | Genentech, Inc., South San Francisco | Zellenzuchtverfahren für glycoproteine |
| CN101255192A (zh) | 2000-05-26 | 2008-09-03 | 布里斯托尔-迈尔斯斯奎布公司 | 可溶性ctla4突变体分子及其应用 |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| KR20030007899A (ko) | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
| HRP20030071B1 (hr) | 2000-07-03 | 2014-01-03 | Bristol-Myers Squibb Company | Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| CA2436139A1 (en) | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| MXPA03010568A (es) | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
| US6951752B2 (en) * | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
| DE60335024D1 (de) * | 2002-12-23 | 2010-12-30 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
| AU2004264901B2 (en) | 2003-08-04 | 2009-12-10 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
-
2003
- 2003-12-18 JP JP2004563965A patent/JP4541157B2/ja not_active Expired - Fee Related
- 2003-12-18 CA CA002511520A patent/CA2511520A1/en not_active Abandoned
- 2003-12-18 BR BR0317723-8A patent/BR0317723A/pt not_active Application Discontinuation
- 2003-12-18 PL PL377731A patent/PL377731A1/pl unknown
- 2003-12-18 AU AU2003300276A patent/AU2003300276B2/en not_active Ceased
- 2003-12-18 KR KR1020057011763A patent/KR20050088136A/ko not_active Ceased
- 2003-12-18 US US10/742,564 patent/US7541164B2/en not_active Expired - Lifetime
- 2003-12-18 TW TW092136008A patent/TWI312368B/zh not_active IP Right Cessation
- 2003-12-18 CN CN2003801099349A patent/CN101044239B/zh not_active Expired - Fee Related
- 2003-12-18 MX MXPA05006523A patent/MXPA05006523A/es active IP Right Grant
- 2003-12-18 WO PCT/US2003/040991 patent/WO2004058800A2/en not_active Ceased
- 2003-12-18 EP EP03814324A patent/EP1575998A4/en not_active Withdrawn
- 2003-12-18 CN CN200910260836A patent/CN101857851A/zh active Pending
-
2009
- 2009-03-18 US US12/381,938 patent/US20120015438A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004058800A2 (en) | 2004-07-15 |
| KR20050088136A (ko) | 2005-09-01 |
| MXPA05006523A (es) | 2005-08-26 |
| AU2003300276B2 (en) | 2010-07-01 |
| US20120015438A1 (en) | 2012-01-19 |
| TWI312368B (en) | 2009-07-21 |
| US7541164B2 (en) | 2009-06-02 |
| EP1575998A4 (en) | 2007-07-25 |
| CA2511520A1 (en) | 2004-07-15 |
| CN101857851A (zh) | 2010-10-13 |
| CN101044239B (zh) | 2010-12-08 |
| CN101044239A (zh) | 2007-09-26 |
| TW200512297A (en) | 2005-04-01 |
| AU2003300276A1 (en) | 2004-07-22 |
| US20050019859A1 (en) | 2005-01-27 |
| WO2004058800A3 (en) | 2007-02-22 |
| JP2006520186A (ja) | 2006-09-07 |
| BR0317723A (pt) | 2005-11-22 |
| EP1575998A2 (en) | 2005-09-21 |
| JP4541157B2 (ja) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL377731A1 (pl) | Sposoby hodowli komórek ssaczych do wytwarzania białka | |
| IL161858A0 (en) | Cell culture process | |
| EP1660629A4 (en) | SYSTEM AND METHOD FOR AUTOMATIC CELL CULTURE | |
| AU2002356749A1 (en) | Process for the production of polypeptides in mammalian cell cultures | |
| EP1488816A4 (en) | CLOSED CELL CULTURE SYSTEM | |
| AU2003274775A1 (en) | Hybrid bioreactor for cell culture | |
| AU2003265094A1 (en) | Method for culturing stem cells | |
| AU2003302701A8 (en) | Method of dynamically culturing embryonic stem cells | |
| GB2404665B (en) | Cell culture | |
| AU2003260351A8 (en) | Cell culture insert | |
| AU2003216822A8 (en) | Stem cell culture | |
| GB0208041D0 (en) | Method of culturing animal cells | |
| GB2386905B (en) | Carrier for cell culture and method for culturing cells | |
| AU2003298523A8 (en) | Methods for efficient production of mammalian recombinant proteins | |
| GB2422843B (en) | Cell culture base | |
| EP1820852A4 (en) | HUMAN SERUM FOR CELL CULTURE | |
| GB0304918D0 (en) | Cell culture | |
| AU2003273715A1 (en) | Improved method for protein production in plant cells | |
| HK1075458A (en) | Mammalian cell culture processes for protein production | |
| AU2003226685A1 (en) | Cell support and method for production thereof | |
| GB0221330D0 (en) | Growth factor for cell culture | |
| SG102044A1 (en) | Cell culture system | |
| GB2394477B (en) | Cell culture | |
| GB0315262D0 (en) | Methods of cell culture | |
| GB0214902D0 (en) | Methods for cell culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |